Castle Biosciences, Inc. (CSTL)
NASDAQ: CSTL · Real-Time Price · USD
25.75
-0.40 (-1.53%)
Feb 21, 2025, 4:00 PM EST - Market closed
Castle Biosciences Employees
Castle Biosciences had 610 employees as of December 31, 2023. The number of employees increased by 67 or 12.34% compared to the previous year.
Employees
610
Change (1Y)
67
Growth (1Y)
12.34%
Revenue / Employee
$511,275
Profits / Employee
$9,959
Market Cap
721.19M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
CSTL News
- 10 days ago - Castle Biosciences to Share Data Reinforcing the Clinical Value of Its Dermatologic Portfolio of Gene Expression Profile Tests at the 22nd Annual Winter Clinical Dermatology Conference - Hawaii® - Business Wire
- 16 days ago - Castle Biosciences to Release Fourth Quarter and Full-Year 2024 Financial Results and Host Conference Call on Thursday, Feb. 27, 2025 - Business Wire
- 5 weeks ago - Castle's Poster on DecisionDx®-SCC Selected as a “Late Breakers” Top Five Finalist for the Akamai Award, Recognizing the Best Posters at Maui Derm Hawaii 2025 - Business Wire
- 5 weeks ago - Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Results - Business Wire
- 6 weeks ago - Castle Biosciences Announces New York State Department of Health Approval of Its TissueCypher® Barrett's Esophagus Test - Business Wire
- 2 months ago - Castle Biosciences Highlights Progress for its Pipeline Atopic Dermatitis Gene Expression Profile Test - Business Wire
- 2 months ago - Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 2 months ago - Independent Systematic Review and Meta-Analysis Attests to the Significant Risk Stratification Provided by Castle Biosciences' DecisionDx®-Melanoma Test, Contributing to Personalized Management of Patients with Melanoma - Business Wire